Effects of chondroitin sulfate and glucosamine in adult patients with Kaschin-Beck disease.
The purpose is to investigate the effects of chondroitin sulfate and glucosamine on adult patients with Kaschin-Beck disease (KBD). A total of 80 patients, aged over 40 years, were randomized into two groups receiving either 1,600 mg oral mixture of chondroitin sulfate and glucosamine or placebo twice daily for 8 months. Posteroanterior radiographs of bilateral knee in full extension were taken at enrollment and after 8 months. Mean joint-space width of the assigned six points on the tibiofemoral joint compartment was measured by a graduated magnifying lens. The mean joint space decreased significantly in the placebo group (4.3 +/- 1.09 versus 4.1 +/- 1.07 mm, P < 0.0001) after 8 months and was unchanged in the experimental group (P = 0.51). There was no statistical significance in the mean joint space between two groups at baseline and follow-up (P = 0.65 and P = 0.84, respectively). But the overall mean change in joint space was significant between the two groups (P < 0.0001). Knee joint space of the experimental group narrowed slowly compared to the control group. Therefore, chondroitin sulfate and glucosamine might play a protective role in preserving articular cartilage and provide evidence for therapeutic drugs in adult patients with KBD.
Zhang
Ya-xu
YX
Key Lab on Etiological Epidemiology, Harbin Medical University, Harbin, China. Dorcas555@163.com
Dong
Wei
W
Liu
Hui
H
Cicuttini
Flavia
F
de Courten
Maximilian
M
Yang
Jian-bai
JB
D000328:Adult; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005944:Glucosamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000139:chemically induced / Q000188:drug therapy*; D013605:T-2 Toxin / Q000633:toxicity*
D004338:Drug Combinations; D002809:Chondroitin Sulfates; D013605:T-2 Toxin; D005944:Glucosamine